We showed by both in silico and in vitro analyses that miR-129-5p is induced by BRAFi or MEKi treatment exclusively in melanoma cell lines with BRAF mutations, and not in primary normal human epidermal melanocytes (NHEMs), BRAF wildtype melanoma cells or BRAFi resistant melanoma cells. The gene discussed is BRAF; the disease is melanoma.